News

Seattle Genetics has posted a net income of $11.46m for the first quarter 2010, or $0.11 per diluted share, compared to net loss of $27.26m, or $0.33 per

Merck KgaA has posted a net income of EUR191.4m for the first quarter 2010, or EUR0.88 per diluted share, compared to EUR56.7, or EUR0.26 per diluted share, for

ProBioGen is expected to contribute producer cell line development and process engineering for one of Virdante’s proprietary therapeutic proteins. Virdante Pharmaceuticals claimed that the protein products are unique

Mantrax facilitates alliances between India, Japan and Australia, particularly in high technology areas, through sourcing from contract research and manufacturing organisations, licensing of intellectual property and value-adding to

Kiadis Pharma said that ATIR continues to show positive clinical results in patients who received a mismatched bone marrow transplantation from a family member donor. ATIR is a

The study is intended to demonstrate the safety and efficacy of PMX-60056 in reversing varying heparin levels, including the highest levels commonly used in surgical settings. Results from

As per the terms of the agreement Pepscan is expected to receive an undisclosed cash payment as well as a minority interest in Immunovo. Wim Mol, CEO of

KRN5500 is a non-opioid analgesic agent, a semi-synthetic derivative of spicamycin: (6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine). As per the terms of the collaboration, NCI is expected to fund the studies and Dara

Abbott said that Kaletra once-daily dosing is already indicated for adult patients new to antiretroviral treatment. This gives treatment-experienced patients who have HIV that responds to Kaletra another